OR WAIT null SECS
IBS care is evolving with personalized, multimodal strategies, but gaps in access, education, and real-world outcomes continue to impact patients’ lives
Irritable bowel syndrome (IBS) remains one of the most common, but complex, gastrointestinal disorders in clinical practice. Defined by abdominal pain and altered bowel habits, IBS has historically been difficult to characterize, treat, and even explain to patients.
In recent years, the field has undergone a meaningful shift, with advances in understanding the gut-brain axis, microbiome, and underlying pathophysiology reshaping how clinicians approach diagnosis and management. At the same time, new therapies and evolving treatment strategies are expanding options for patients.
Adelina Hung, MD: clinical assistant professor at Rosalind Franklin University Chicago Medical School and director of the IBD program at Sinai Health System Chicago
Ali Rezaie, MD: medical director of the GI Motility Program at Cedars-Sinai
Caroline Soyka, DO: gastroenterologist with Baptist Health South Florida
As IBS Awareness Month highlights both progress and ongoing needs, experts emphasize a dual reality: care is improving, but major gaps remain.
For decades, IBS was categorized as a “functional” disorder, a label that often reflected uncertainty around its biological basis. Today, that framework is rapidly evolving.
“Our understanding of IBS has expanded significantly, leading to meaningful changes in how we approach disease management,” said HCPLive advisory board member Adelina Hung, MD. “It is increasingly recognized as a complex disorder of the gut-brain-microbiome rather than the traditional ‘functional’ condition.”
This shift reflects growing recognition that IBS arises from multiple interacting mechanisms, including dysregulation of the gut-brain axis, microbial imbalance, altered motility, immune activation, and visceral hypersensitivity. Rather than a single disease entity, IBS is now widely viewed as a spectrum of related conditions with overlapping features.
That complexity has important implications for care. Because the condition is highly heterogeneous with symptoms that vary widely between patients, standardized treatment approaches are inherently limited.
Historically, IBS management focused on symptom relief, including antidiarrheals for IBS-D, laxatives for IBS-C, and general dietary advice. While these strategies remain important and still play an important role in care, they are no longer seen as sufficient as standalone approaches.
In an interview with HCPLive, Ali Rezaie, MD, noted that the field has moved away from purely empirical treatment toward more tailored strategies informed by underlying mechanisms.
“20 or 30 years ago, we would empirically treat patients, mostly just targeting symptoms,” he explained. “Now, we recognize that IBS has multiple underlying pathophysiologies, and depending on the patient, we can tailor therapy more precisely.”
Modern care begins with a thorough evaluation to exclude alarm features and conditions that may mimic IBS, such as inflammatory bowel disease or malignancy. From there, clinicians can build a layered treatment approach that integrates lifestyle changes, pharmacotherapy, and targeted interventions based on symptom patterns and suspected drivers.
Dietary modification remains a cornerstone, but its effectiveness is often limited, with many patients ultimately requiring pharmacologic therapy and treatment selection guided by predominant symptoms such as constipation, diarrhea, or bloating.
Although several US Food and Drug Administration (FDA)-approved medications are now available, most continue to focus on symptom control rather than addressing root causes, a limitation that underscores the need for continued therapeutic innovation.
Recent years have brought important developments in IBS therapeutics, reflecting both incremental progress and broader shifts in treatment philosophy.
New investigational agents are exploring novel mechanisms across IBS subtypes, one of the most recent being EnteroBiotix Limited’s EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic for IBS-C and IBS-D. In the phase 2a TrIuMPH trial, EBX-102-02 demonstrated clinically meaningful improvements in the IBS symptom severity score versus placebo, with clear separation from placebo observed as early as week 1 and sustained throughout the 6-week follow up period in both the IBS-C and IBS-D cohorts.
At the same time, regulatory milestones like the FDA approval of linaclotide (Linzess) for pediatric IBS-C are expanding access to care for younger patients. In November 2025, the guanylate cyclase C agonist from Ironwood Pharmaceuticals was approved for pediatric patients ≥ 7 years of age with IBS-C, making it the first treatment approved for IBS-C in this patient population.
Growing attention is also being paid to microbiome-directed therapies. Research suggests that, for some patients, alterations in the gut microbiome may play a central role in symptom development.
“There is no doubt that a subgroup of IBS patients has disease driven by the gut microbiome,” Rezaie said.
This recognition has supported the use of targeted interventions such as antibiotics, dietary strategies, and other microbiome-modulating approaches in select patients. However, identifying which patients will benefit most remains an ongoing challenge.
As understanding of IBS has evolved, so has the approach to treatment. Care is increasingly being defined not by a single intervention, but by a combination of strategies tailored to the individual.
“Treatment involves a combination of diet, medications, lifestyle changes, and adjunctive therapy like CBT, hypnosis, acupuncture, and yoga,” Caroline Soyka, DO, told HPCLive.
This multimodal framework reflects the interconnected nature of IBS pathophysiology, particularly the role of the gut-brain axis. Behavioral therapies, in particular, are gaining recognition for their ability to address symptom perception, stress response, and central processing of pain.
Rather than prioritizing one modality over another, Soyka said she approaches treatment as a collaborative process shaped by patient preferences, disease severity, and response to prior therapies. In a condition where no single treatment works universally, this flexibility is critical.
One of the defining features of IBS is its chronicity. Many patients are diagnosed in early adulthood and require long-term management, often with periods of symptom fluctuation.
“A lot of patients are diagnosed in their 20s, 30s, or 40s,” Rezaie said. “If you start them on a medication, this is not necessarily a curable disease, so they might be on that medication for years or decades.”
This reality makes expectation-setting a key component of care. Clinicians must balance the goal of symptom improvement with the understanding that complete resolution is often unrealistic.
Soyka emphasized the importance of reframing success for patients, particularly those with persistent or refractory symptoms.
“I remind [my patients] that we are not always aiming for perfection, but rather improvement each time,” she said.
This approach can help patients remain engaged in care while navigating the trial-and-error process that often accompanies IBS management.
Despite advances in understanding and treatment, IBS care often remains inconsistent in practice. One major challenge is the condition’s lack of a clear, algorithmic treatment pathway.
IBS requires individualized care, extensive patient education, and often ongoing adjustments to therapy, all of which are factors that can be difficult to accommodate in routine clinical settings. As a result, care may vary significantly depending on provider experience and available resources.
Soyka noted that many clinicians receive limited formal training in IBS, particularly in areas such as the gut-brain axis and microbiome-targeted therapies. This gap can contribute to variability in care and underutilization of certain treatment modalities. Access also remains a barrier, especially for non-pharmacologic interventions like cognitive behavioral therapy and complementary therapies, which are not always covered by insurance.
At the same time, real-world data suggest that these gaps continue to have a measurable impact on patients’ daily lives. Findings from the 2024 IBS in America survey indicate that IBS symptoms interfere with work productivity for nearly 11 days each month, while also disrupting personal and social activities for approximately 8 days monthly. Absenteeism has increased compared with prior years, and fewer than one-third of patients report being able to reliably predict when symptoms will occur, underscoring the persistent unpredictability of the condition.
Taken together, these data highlight a disconnect between advances in clinical knowledge and the lived experience of patients. While therapeutic options have expanded and understanding of IBS pathophysiology has deepened, many patients continue to face significant functional impairment and reduced quality of life.
Meanwhile, the underlying heterogeneity of IBS continues to complicate both diagnosis and treatment selection, reinforcing the need for more precise tools and biomarkers to guide care.
The future of IBS care will likely be shaped by continued advances in microbiome science and precision medicine. Researchers are working to better characterize the diverse biological pathways involved in IBS and to identify targeted interventions for specific patient subgroups.
“The fecal microbiome holds so much of the key,” Soyka said.
However, translating this promise into clinical practice will require overcoming significant challenges. The microbiome is highly individualized and dynamic, making it difficult to define universal targets or standardized interventions.
Still, the broader trajectory of IBS research is clear: toward more personalized, mechanism-based care that moves beyond symptom management alone. As IBS Awareness Month underscores, the progress is real, but so is the work that remains.
Related Content:
